Aerospace and defense company BWX (NYSE:BWXT) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 13% year on year to $682.3 million. On the other hand, the company’s full-year revenue guidance of $3 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.91 per share was 19.6% above analysts’ consensus estimates.

Is now the time to buy BWXT? Find out in our full research report (it’s free).

BWX (BWXT) Q1 CY2025 Highlights:

Revenue: $682.3 million vs analyst estimates of $648.9 million (13% year-on-year growth, 5.1% beat) Adjusted EPS: $0.91 vs analyst estimates of $0.76 (19.6% beat) Adjusted EBITDA: $129.8 million vs analyst estimates of $118.6 million (19% margin, 9.4% beat) The company reconfirmed its revenue guidance for the full year of $3 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $3.47 at the midpoint EBITDA guidance for the full year is $560 million at the midpoint, above analyst estimates of $554.4 million Operating Margin: 14.2%, down from 15.4% in the same quarter last year Free Cash Flow Margin: 2.5%, up from 0.4% in the same quarter last year Backlog: $4.88 billion at quarter end Market Capitalization: $10.02 billion

StockStory’s Take

BWX Technologies’ Q1 results were driven by significant contract wins in both government and commercial operations, as well as steady execution across its portfolio. CEO Rex Geveden highlighted increased demand for nuclear technologies, noting, "Our first quarter financial performance exceeded expectations highlighted by double-digit year-over-year revenue, adjusted EBITDA and adjusted earnings per share growth." He also pointed to strategic wins, such as the Department of Energy’s Strategic Petroleum Reserve contract, as reinforcing BWXT's value proposition in energy security.

Looking ahead, management reaffirmed its full-year outlook but acknowledged some near-term headwinds. CFO Robb LeMasters explained that while the company’s first quarter outperformance benefited from material procurement timing, margins in certain segments are facing temporary pressures from higher input costs. The team emphasized ongoing investments to meet anticipated customer demand, especially in nuclear power and medical isotopes, while closely monitoring raw material inflation and regulatory developments that could influence results in future quarters.

Key Insights from Management’s Remarks

Management’s commentary on the Q1 earnings call emphasized demand momentum, strategic contract awards, and actions taken to address margin pressures. Several key developments are shaping BWXT’s business trajectory:

Story Continues

Contract Wins and Backlog Expansion: BWXT secured new contracts, including leading the Department of Energy’s Strategic Petroleum Reserve and a sole-source designation for the Domestic Uranium Enrichment Centrifuge Experiment (DUECE) pilot. This expanded the company’s backlog, particularly in commercial operations, where bookings rose 78% year-over-year. Growing Government Operations: The government segment posted 14% revenue growth, attributed to timing of material procurement, ramp-up in U-Metal production, and the A.O.T. acquisition. Management noted this area is well-supported by long-cycle contracts tied to naval nuclear propulsion and defense modernization priorities. Commercial Power and Nuclear Medicine Momentum: Commercial operations saw strong bookings, especially for the Pickering life extension project and SMR (small modular reactor) components. The medical segment delivered double-digit growth, driven by PET diagnostic products and ongoing investments in radiopharmaceutical innovation. Margin Pressures and Recovery Plans: Management acknowledged operating margin compression, citing cost absorption challenges and inflation in specialized raw materials like zirconium. They expect these pressures to persist through Q2 before contractual recovery mechanisms ease the impact in the second half of the year. Strategic Acquisitions and Capacity Expansion: The acquisition of A.O.T. is now fully integrated, with early upside potential in supplying high-purity depleted uranium for national security. The planned Kinectrics acquisition will broaden BWXT’s nuclear services, and the Cambridge manufacturing expansion is ahead of schedule, set to boost production capacity by nearly 50%.

Drivers of Future Performance

Management projects steady revenue and earnings growth for the rest of 2025, anchored by a robust backlog and strategic investments. The outlook is shaped by opportunities in defense, energy, and medical markets, but also acknowledges near-term operational risks and input cost volatility.

Defense and Nuclear Industry Demand: Long-cycle contracts in naval propulsion, defense enrichment, and government services underpin revenue visibility, with new government priorities and funding initiatives potentially creating additional upside. Commercial Power Expansion: Ongoing investments in commercial nuclear infrastructure, including the Pickering project and SMR programs, are expected to drive double-digit organic revenue growth in commercial operations, augmented by the Kinectrics acquisition. Margin and Cost Control Risks: Management flagged that inflation in raw materials, particularly zirconium, will constrain margins in the first half. Recovery is expected from contractual pass-through mechanisms and improved operating leverage in the back half of the year, but cost management remains a key risk.

Top Analyst Questions

Scott Deuschle (Deutsche Bank): Asked about the impact of negative EACs (Estimate at Completion adjustments) and if margin strength could be sustained. Management clarified EACs were split across commercial and government, with raw material cost recoveries expected later in the year. Pete Skibitski (Alembic Global): Inquired about potential government funding from recent bills and its effect on BWXT. Leadership noted limited near-term impact but highlighted optimism about future defense enrichment and DoD reactor opportunities. Bob Labick (CJS Securities): Sought clarity on the timeline for FDA approval and commercialization of BWXT’s medical isotope products. CEO Rex Geveden indicated approval could still arrive in 2025 but acknowledged possible delays into early 2026. Thomas Meric (Janney Montgomery): Requested details on the Domestic Uranium Enrichment Centrifuge Experiment pilot and BWXT’s strategy for the HALEU (High-Assay Low-Enriched Uranium) market. Management described the program as in early conceptual design, with future phases dependent on government acquisition strategies. Andre Madrid (BTIG): Asked about inflationary pressures in zirconium supply and BWXT’s ability to manage these costs. Leadership pointed to contractual cost pass-throughs with customers and existing hedging strategies to mitigate risk.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) progress on integrating the Kinectrics acquisition and its effect on commercial revenue growth, (2) the pace of margin recovery as cost pass-throughs on raw materials take effect, and (3) developments in key government contracts, especially in enrichment and defense. Execution on major infrastructure projects and regulatory milestones in the medical segment will also be important markers for future performance.

BWX currently trades at a forward P/E ratio of 30.5×. At this valuation, is it a buy or sell post earnings? Find out in our free research report.

Stocks That Trumped Tariffs in 2018

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

View Comments